358 related articles for article (PubMed ID: 1740679)
1. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
4. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
5. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Estey E; Thall PF; Kantarjian H; O'Brien S; Koller CA; Beran M; Gutterman J; Deisseroth A; Keating M
Blood; 1992 May; 79(9):2246-55. PubMed ID: 1571541
[TBL] [Abstract][Full Text] [Related]
6. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin in blastic crisis of chronic myelogenous leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
12. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Kantarjian HM; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios MB; Smith TL; Calvert L; Deisseroth AB
J Clin Oncol; 1995 Mar; 13(3):553-9. PubMed ID: 7884415
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
Bettelheim P; Valent P; Andreeff M; Tafuri A; Haimi J; Gorischek C; Muhm M; Sillaber C; Haas O; Vieder L
Blood; 1991 Feb; 77(4):700-11. PubMed ID: 1993213
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S
Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
18. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
19. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Gandhi V; Du M; Kantarjian HM; Plunkett W
Leukemia; 1994 Sep; 8(9):1463-8. PubMed ID: 8090026
[TBL] [Abstract][Full Text] [Related]
20. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Kantarjian HM; Estey EH; O'Brien S; Anaissie E; Beran M; Rios MB; Keating MJ; Gutterman J
Blood; 1992 Feb; 79(4):876-81. PubMed ID: 1737098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
